GC BIOPHARMA CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119,900 KRW | +1.18% |
|
+8.41% | -4.46% |
| 05-20 | Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval | CI |
| 05-16 | GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GC BIOPHARMA CORP. | Other Pharmaceuticals | +1.18% | +8.41% | -4.46% | -4.92% | +0.33% | 991M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- A006280 Stock
- Charts GC Biopharma Corp.
- Comparison Chart
